Advances in Antibody-Based Therapeutics: From Design to Clinical Applications
DOI:
https://doi.org/10.36676/ssjmra.v1.i2.01Keywords:
Antibody-based therapeutics, monoclonal antibodies, antibody engineering, antibody designAbstract
Advances in Antibody-Based Therapeutics: From Design to Clinical Applications provides a comprehensive overview of the latest developments in antibody-based therapeutics, spanning from initial design concepts to their translation into clinical practice. This paper explores the innovative strategies and technologies driving the evolution of antibody engineering and their diverse applications in the treatment of various diseases.Antibodies, key components of the immune system, have emerged as powerful tools for targeted therapy due to their exquisite specificity and versatility. Over the years, significant progress has been made in the design and optimization of antibodies, leveraging advances in biotechnology, protein engineering, and computational modeling.The design phase of antibody-based therapeutics encompasses a range of approaches, including the generation of monoclonal antibodies (mAbs) through hybridoma technology, phage display, and recombinant DNA techniques. These methods enable the production of antibodies with tailored properties, such as enhanced affinity, specificity, and stability, to target specific antigens associated with disease.In addition to their traditional role in treating infectious diseases, antibodies have revolutionized the field of oncology with the development of antibody-drug conjugates (ADCs), bispecific antibodies, and immune checkpoint inhibitors. These next-generation therapeutics offer novel mechanisms of action, enabling targeted delivery of cytotoxic agents, immune cell activation, and modulation of immune responses against cancer cells.
References
Köhler, G., & Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256(5517), 495–497. This foundational paper describes the original development of monoclonal antibody technology.
Carter, P. J. (2006). Potent antibody therapeutics by design. Nature Reviews Immunology, 6(5), 343-357. This review discusses the design strategies to enhance the potency, specificity, and therapeutic index of antibody therapeutics.
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017). Strategies and challenges for the next generation of antibody-drug conjugates. Nature Reviews Drug Discovery, 16(5), 315-337. This paper reviews the strategies to improve antibody-drug conjugates, a significant class of therapeutic agents.
Kontermann, R. E. (2015). Dual targeting strategies with bispecific antibodies. MAbs, 7(1), 9-23. This article provides an overview of bispecific antibodies and their potential in therapeutic applications.
Weiner, G. J. (2015). Building better monoclonal antibody-based therapeutics. Nature Reviews Cancer, 15(6), 361-370. This review covers the modifications to antibody structure to improve therapeutic outcomes in cancer treatment.
Thakur, A., Huang, M., & Lum, L. G. (2020). Bispecific antibody based therapeutics: Strengths and challenges. Blood Reviews, 37, 100648. This paper discusses the recent advances and challenges in the development of bispecific antibodies.
Chames, P., & Baty, D. (2009). Bispecific antibodies for cancer therapy: The light at the end of the tunnel? MAbs, 1(6), 539-547. This review discusses the therapeutic potential of bispecific antibodies in cancer therapy.
Shields, R. L., et al. (2001). High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. Journal of Biological Chemistry, 276(9), 6591-6604. This study discusses the engineering of antibodies for enhanced therapeutic efficacy.
Almagro, Juan C., Tracy R. Daniels-wells, and Sonia Mayra Perez-tapia. 2018. “Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy.” 8(January). doi: 10.3389/fimmu.2017.01751.
Goswami, Sumit, Wei Wang, Tsutomu Arakawa, and Satoshi Ohtake. 2013. “Developments and Challenges for MAb-Based Therapeutics.” 89:452–500. doi: 10.3390/antib2030452.
Goydel, Rebecca S., and Christoph Rader. 2021. “Antibody-Based Cancer Therapy.” 40(21):3655–64. doi: 10.1038/s41388-021-01811-8.Antibody-based.
Heo, Yong-seok. 2022. “Recent Advances in Antibody Therapeutics.” 33:10–12.
Lopes, Mariana, Wagner Quintilio, Tania Maria Manieri, Lilian Rumi Tsuruta, and Ana Maria Moro. 2017. “Advances and Challenges in Therapeutic Monoclonal Antibodies Drug Development.” 1–15.
Sifniotis, Vicki, Esteban Cruz, Barbaros Eroglu, and Veysel Kayser. 2019. “Current Advancements in Addressing Key Challenges of Therapeutic Antibody Design , Manufacture , and Formulation.” (December 2018).
T Mohammad Tabrizi 2013 . “Development of Antibody-Based Therapeutics”.
Zhong, Xiaotian, and Aaron M. D. Antona. 2021. “Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics.”
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Shodh Sagar Journal for Medical Research Advancement
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.